Cancer screening blood test based on single-molecule liquid biopsy (enzymes measured at the single-molecule level).
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Series A Cosomil raised a Series A1 of undisclosed amount led by Delight Ventures for its pancreatic cancer screening blood test. | — |
| Nov 2023 | Series A Cosomil, a Univ. of Tokyo/RIKEN spinout developing a liquid-biopsy test for early pancreatic cancer detection, raised an undisclosed pre-Series A round. | — |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.